Medicare Enrolled
Dr. Praveen Reddy, MD
Hematology & Oncology · Wichita Falls, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Reddy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reddy? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Reddy
Dr. Praveen Reddy is a hematology & oncology in Wichita Falls, TX, with 19 years in practice. Based on federal Medicare data, Dr. Reddy performed 409,300 Medicare services across 9,315 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reddy received a total of $6,282 from 36 pharmaceutical and/or device companies across 89 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reddy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 0% volume in TX$ $6,282 industry payments
Medicare Practice Summary
Medicare Utilization ↗409,300
Medicare services
Top 0% in TX for hematology & oncology
9,315
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~21,542 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 243,270 | $0 | $5 |
| Filgrastim injection (Nivestym) for white blood cells | 38,760 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 21,190 | $2 | $20 |
| Iron sucrose injection (Venofer) | 15,200 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 15,100 | $43 | $136 |
| Azacitidine chemotherapy injection | 12,500 | $0 | $13 |
| Oxaliplatin chemotherapy injection | 11,900 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 9,860 | $0 | $3 |
| Anti-nausea injection (fosaprepitant) | 4,800 | $0 | $5 |
| Paclitaxel chemotherapy injection | 4,320 | $0 | $8 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,860 | $22 | $181 |
| Blood draw (venipuncture) | 2,834 | $8 | $20 |
| Complete blood count (CBC) with differential | 2,703 | $8 | $36 |
| Dexamethasone injection (steroid) | 2,423 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 2,220 | $18 | $66 |
| Comprehensive metabolic blood panel | 1,508 | $10 | $64 |
| Office visit, established patient (20-29 min) | 1,428 | $62 | $250 |
| Iron level test | 1,415 | $6 | $27 |
| Iron binding capacity test | 1,415 | $9 | $35 |
| Ferritin level test (iron stores) | 1,414 | $13 | $60 |
| Injection, leucovorin calcium, per 50 mg | 1,338 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 922 | $2 | $13 |
| Office visit, established patient (30-39 min) | 787 | $88 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 690 | $0 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 679 | $47 | $313 |
| Injection of additional new drug or substance into vein | 575 | $12 | $108 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 504 | $82 | $1,348 |
| Anti-nausea injection (Aloxi/palonosetron) | 480 | $1 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 433 | $96 | $707 |
| Injection, carboplatin, 50 mg | 366 | $2 | $300 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 312 | $20 | $128 |
| Drug injection, under skin or into muscle | 307 | $10 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 251 | $22 | $157 |
| Injection, zoledronic acid, 1 mg | 221 | $6 | $431 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 220 | $3 | $373 |
| Carcinoembryonic antigen (cea) protein level | 217 | $19 | $99 |
| Complete blood count (CBC), automated | 208 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 207 | $4 | $22 |
| New patient office visit (45-59 min) | 207 | $109 | $565 |
| Administration of chemotherapy into vein, each additional hour | 192 | $21 | $161 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 164 | $456 | $1,414 |
| Administration of additional new drug or substance into vein, 1 hour or less | 160 | $48 | $344 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 150 | $1,103 | $4,802 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 150 | $54 | $211 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 145 | $345 | $1,722 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 143 | $90 | $657 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 143 | $272 | $2,762 |
| Injection, magnesium sulfate, per 500 mg | 138 | $1 | $6 |
| Irrigation of implanted venous access drug delivery device | 137 | $17 | $114 |
| Lactate dehydrogenase (enzyme) level | 126 | $6 | $31 |
| Injection, diphenhydramine hcl, up to 50 mg | 122 | $1 | $7 |
| Administration of additional new drug or substance into vein using push technique | 118 | $42 | $289 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 116 | $24 | $145 |
| Magnesium level test | 99 | $7 | $29 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 96 | $123 | $500 |
| Ct scan of chest with contrast | 94 | $48 | $821 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 78 | $15 | $94 |
| CT scan of abdomen and pelvis with contrast | 71 | $165 | $1,067 |
| Unclassified drugs | 69 | $1 | $8 |
| Infusion, normal saline solution , 1000 cc | 68 | $2 | $19 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 68 | $73 | $70 |
| Red blood count automated, with additional calculations | 59 | $5 | $26 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 56 | $133 | $3,675 |
| PSA test (prostate cancer screening) | 52 | $18 | $94 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 51 | $15 | $100 |
| Drawing of blood for a medical problem | 44 | $63 | $264 |
| Application of on-body injector for under skin injection | 43 | $14 | $96 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 43 | $178 | $700 |
| Blood creatinine level | 38 | $5 | $31 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 37 | $1 | $19 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 32 | $4 | $25 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 31 | $177 | $700 |
| Infusion into a vein for hydration, 31-60 minutes | 23 | $23 | $256 |
| CT scan of chest, without contrast | 21 | $43 | $686 |
| Infusion into a vein for hydration, each additional hour | 20 | $10 | $75 |
| Ct scan of soft tissue of neck with contrast | 19 | $48 | $658 |
| Vitamin B-12 level test | 14 | $15 | $76 |
| Ct scan of abdomen and pelvis without contrast | 13 | $75 | $560 |
| Nuclear medicine study whole body with ct scan | 13 | $1,109 | $4,929 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
59.8% high complexity
36.3% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,282
Total received (2018-2024)
Avg $897/year across 7 years
Top 39% in TX for hematology & oncology
36
Companies
89
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,250 (51.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,075 (33.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$957 (15.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$354
2023$606
2022$669
2021$3,090
2020$451
2019$539
2018$573
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AbbVie Inc.
$1,575
Lilly USA, LLC
$573
EMD Serono, Inc.
$500
PFIZER INC.
$300
AstraZeneca Pharmaceuticals LP
$275
Astellas Pharma US Inc
$239
GlaxoSmithKline, LLC.
$222
Pharmacyclics LLC, An AbbVie Company
$220
Celgene Corporation
$185
Adaptive Biotechnologies Corporation
$183
Seagen Inc.
$176
Takeda Pharmaceuticals U.S.A., Inc.
$148
Incyte Corporation
$145
PUMA BIOTECHNOLOGY, INC.
$135
Pharmacosmos Therapeutics Inc.
$125
Rigel Pharmaceuticals, Inc.
$125
Blueprint Medicines Corporation
$123
Puma Biotechnology, Inc.
$119
Verastem, Inc.
$117
Exelixis Inc.
$106
SANOFI-AVENTIS U.S. LLC
$100
Tempus AI, Inc
$84
Janssen Biotech, Inc.
$80
GENZYME CORPORATION
$63
ABBVIE INC.
$58
Bayer HealthCare Pharmaceuticals Inc.
$52
Gilead Sciences, Inc.
$45
Karyopharm Therapeutics Inc.
$39
Sun Pharmaceutical Industries Inc.
$37
Eisai Inc.
$25
Pharmacyclics LLC, an AbbVie Company
$23
CTI BioPharma Corp.
$18
Merck Sharp & Dohme LLC
$18
Regeneron Healthcare Solutions, Inc.
$18
Kite Pharma, Inc.
$16
Acrotech Biopharma LLC
$12
Top 3 companies account for 42.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · BELEODAQ · BOSULIF · CABLIVI · Cabometyx · Copiktra · DAURISMO · ELIQUIS · EPKINLY · ERLEADA · GAVRETO · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEMPERLI · KEYTRUDA · LIBTAYO · Lenvima · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · OJJAARA · Odomzo · PADCEV · REBLOZYL · Revlimid · Rezlidhia · SARCLISA · SUTENT · TAGRISSO · TALZENNA · Tavalisse · Tepmetko · Trodelvy · VENCLEXTA · VERZENIO · Vonjo · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (52%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
1
Per 100K population
0.8
County median income
$62,168
Nearest hospital
UNITED REGIONAL HEALTH CARE SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Reddy is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Reddy experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Reddy performed 243,270 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reddy receive payments from pharmaceutical companies?
Yes. Dr. Reddy received a total of $6,282 from 36 companies across 89 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reddy's costs compare to other hematology & oncologys in Wichita Falls?
Dr. Reddy's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reddy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Wichita Falls
Browse hematology & oncologys in Wichita Falls ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc..
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology